The biosimilar brand of etanercept Rymti, Etera has been approved by the TGA for use in conditions including rheumatoid arthritis, psoriatic arthritis and non-radiographic axial spondyloarthritis.
The TNF inhibitor, marketed by Lupin Australia is indicated for the treatment of RA, PsA, nr-AxSpa, ankylosing spondylitis, juvenile idiopathic arthritis and plaque psoriasis.
It is a biosimilar for Pfizer’s Enbrel, which has been available in Australia since 2005, and joins other biosimilars such as Brenzys and Erelzi.